nCounter® Autoimmune Discovery Panel
Helping Your Research
The nCounter Autoimmune Discovery Panel is designed to enable researchers to discover links between known autoimmune disease associated germline variants and gene expression. The genes were selected in collaboration with leading autoimmune researchers and are linked to the top nine autoimmune diseases.
This panel is a Curated Gene List: application and pathway-specific content pre-designed and developed by NanoString available for custom ordering. You can add up to 55 gene targets to it with a “Plus” option to customize the panel to your research project.
Panel Selection Tool
Find the gene expression panel for your research with easy to use panel pro
Find Your Panel
Product Information
Coverage of Autoimmune Diseases
Disease-specific annotations for nine autoimmune disease types and human immune response genes were assigned across all genes in the autoimmune discovery panel, allowing for the identification of gene functions and signatures for all autoimmune diseases.
Related Resources
Publications
Therapeutically expanded human regulatory T-cells are super-suppressive due to HIF1A induced expression of CD73
The adoptive transfer of regulatory T-cells (Tregs) is a promising therapeutic approach in transplantation and autoimmunity. However, because large cell numbers are needed to achieve a therapeutic effect, in vitro expansion is required.
Gene Expression Analysis in Four Dogs With Canine Pemphigus Clinical Subtypes Reveals B Cell Signatures and Immune Activation Pathways Similar to Human Disease
Pemphigus is a group of autoimmune-mediated mucocutaneous blistering diseases characterized by acantholysis. Pemphigus has also been recognized in dogs and shares similar clinical characteristics and variants with human pemphigus.
Genetic in situ engineering of myeloid regulatory cells controls inflammation in autoimmunity
The ability of myeloid regulatory cells (MRCs) to control immune responses and to promote tolerance has prompted enormous interest in exploiting them therapeutically to treat inflammation, autoimmunity, or to improve outcomes in transplantation. While immunomodulatory small-molecule compounds and antibodies have provided relief for some patients, the dosing entails high systemic drug exposures and thus increased risk of off-target adverse effects.
Request a Quote
Contact our helpful experts and we’ll be in touch soon.
